Greg Zante - 03 Jan 2022 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Financial Officer
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
03 Jan 2022
Net transactions value
-$55,931
Form type
4
Filing time
05 Jan 2022, 18:13:27 UTC
Previous filing
30 Sep 2021
Next filing
04 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Tax liability $15,113 -3,097 -3.3% $4.88 91,806 03 Jan 2022 Direct F1, F2
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +53,333 +58% $0.000000 145,139 03 Jan 2022 Direct F3
transaction VKTX Common Stock, par value $0.00001 per share Tax liability $40,818 -8,835 -6.1% $4.62 136,304 04 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Award $0 +120,000 $0.000000 120,000 03 Jan 2022 Common Stock 120,000 $4.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
F2 Includes 418 shares acquired on November 19, 2021 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3 Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date.
F4 25% of the shares subject to the option will vest on each anniversary of the grant date.